4//SEC Filing
Flagship Ventures Fund IV General Partner LLC 4
Accession 0000899243-20-014188
CIK 0001682852other
Filed
May 25, 8:00 PM ET
Accepted
May 26, 5:00 PM ET
Size
43.7 KB
Accession
0000899243-20-014188
Insider Transaction Report
Form 4
Moderna, Inc.MRNA
Transactions
- Sale
Common Stock
2020-05-21$70.46/sh−3,900$274,780→ 6,503,684 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$72.44/sh−367$26,584→ 6,500,766 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$69.45/sh−363,594$25,250,331→ 22,042,805 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$67.15/sh−121,771$8,176,971→ 22,481,314 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$70.46/sh−20,492$1,443,793→ 22,421,740 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$72.44/sh−1,933$140,017→ 22,406,399 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$71.51/sh−2,551$182,433→ 6,501,133 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$68.81/sh−39,082$2,689,404→ 22,442,232 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$71.51/sh−13,408$958,861→ 22,408,332 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$65.77/sh−42,540$2,797,690→ 6,538,226 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$68.81/sh−7,443$512,185→ 6,507,584 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$65.77/sh−223,314$14,686,491→ 22,603,085 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$70.18/sh−56,406$3,958,353→ 21,986,399 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$70.18/sh−10,746$754,113→ 6,420,766 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$67.15/sh−23,199$1,557,822→ 6,515,027 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$69.45/sh−69,254$4,809,448→ 6,431,512 total(indirect: See Footnote)
Holdings
- 1,389,827(indirect: See Footnote)
Common Stock
- 3,924(indirect: See Footnote)
Common Stock
- 11,460,435(indirect: See Footnote)
Common Stock
Flagship Ventures Fund IV, L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-05-21$72.44/sh−1,933$140,017→ 22,406,399 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$65.77/sh−42,540$2,797,690→ 6,538,226 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$68.81/sh−7,443$512,185→ 6,507,584 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$72.44/sh−367$26,584→ 6,500,766 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$70.18/sh−56,406$3,958,353→ 21,986,399 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$65.77/sh−223,314$14,686,491→ 22,603,085 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$68.81/sh−39,082$2,689,404→ 22,442,232 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$71.51/sh−13,408$958,861→ 22,408,332 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$67.15/sh−23,199$1,557,822→ 6,515,027 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$70.46/sh−3,900$274,780→ 6,503,684 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$71.51/sh−2,551$182,433→ 6,501,133 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$69.45/sh−363,594$25,250,331→ 22,042,805 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$69.45/sh−69,254$4,809,448→ 6,431,512 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$67.15/sh−121,771$8,176,971→ 22,481,314 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$70.46/sh−20,492$1,443,793→ 22,421,740 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$70.18/sh−10,746$754,113→ 6,420,766 total(indirect: See Footnote)
Holdings
- 11,460,435(indirect: See Footnote)
Common Stock
- 3,924(indirect: See Footnote)
Common Stock
- 1,389,827(indirect: See Footnote)
Common Stock
Flagship Ventures Fund IV-Rx, L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-05-21$70.46/sh−3,900$274,780→ 6,503,684 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$70.18/sh−10,746$754,113→ 6,420,766 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$69.45/sh−69,254$4,809,448→ 6,431,512 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$65.77/sh−42,540$2,797,690→ 6,538,226 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$71.51/sh−2,551$182,433→ 6,501,133 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$72.44/sh−367$26,584→ 6,500,766 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$67.15/sh−121,771$8,176,971→ 22,481,314 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$70.46/sh−20,492$1,443,793→ 22,421,740 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$72.44/sh−1,933$140,017→ 22,406,399 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$69.45/sh−363,594$25,250,331→ 22,042,805 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$71.51/sh−13,408$958,861→ 22,408,332 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$65.77/sh−223,314$14,686,491→ 22,603,085 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$68.81/sh−39,082$2,689,404→ 22,442,232 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$67.15/sh−23,199$1,557,822→ 6,515,027 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$70.18/sh−56,406$3,958,353→ 21,986,399 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$68.81/sh−7,443$512,185→ 6,507,584 total(indirect: See Footnote)
Holdings
- 11,460,435(indirect: See Footnote)
Common Stock
- 3,924(indirect: See Footnote)
Common Stock
- 1,389,827(indirect: See Footnote)
Common Stock
AFEYAN NOUBAR
Director
Transactions
- Sale
Common Stock
2020-05-21$65.77/sh−223,314$14,686,491→ 22,603,085 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$68.81/sh−39,082$2,689,404→ 22,442,232 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$71.51/sh−13,408$958,861→ 22,408,332 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$67.15/sh−23,199$1,557,822→ 6,515,027 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$70.46/sh−3,900$274,780→ 6,503,684 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$71.51/sh−2,551$182,433→ 6,501,133 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$70.18/sh−10,746$754,113→ 6,420,766 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$67.15/sh−121,771$8,176,971→ 22,481,314 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$72.44/sh−367$26,584→ 6,500,766 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$69.45/sh−363,594$25,250,331→ 22,042,805 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$72.44/sh−1,933$140,017→ 22,406,399 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$68.81/sh−7,443$512,185→ 6,507,584 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$69.45/sh−69,254$4,809,448→ 6,431,512 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$70.46/sh−20,492$1,443,793→ 22,421,740 total(indirect: See Footnote) - Sale
Common Stock
2020-05-21$65.77/sh−42,540$2,797,690→ 6,538,226 total(indirect: See Footnote) - Sale
Common Stock
2020-05-22$70.18/sh−56,406$3,958,353→ 21,986,399 total(indirect: See Footnote)
Holdings
- 1,389,827(indirect: See Footnote)
Common Stock
- 11,460,435(indirect: See Footnote)
Common Stock
- 3,924(indirect: See Footnote)
Common Stock
Footnotes (13)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.435 to $66.425, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.10 to $70.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F11]Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
- [F12]Shares held by Flagship Pioneering, Inc. ("Pioneering"). Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Pioneering. Each of the reporting persons except for Pioneering disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
- [F13]Shares held by Noubar B. Afeyan, Ph.D. Each of the reporting persons except for Noubar B. Afeyan, Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
- [F2]Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partners LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.50 to $69.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.22 to $72.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F8]Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.10 to $70.095, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Documents
Issuer
Moderna, Inc.
CIK 0001682852
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001508051
Filing Metadata
- Form type
- 4
- Filed
- May 25, 8:00 PM ET
- Accepted
- May 26, 5:00 PM ET
- Size
- 43.7 KB